for immediate release kyowa hakko reports earnings fiscal year ended march 31 2002 tokyo may 15 jcn newswire kogyo co ltd one of japan s leading makers pharmaceuticals and bio chemicals reported that sales the full rose 0 8 percent to 378 7 billion yen operating profit 14 9 20 4 while net income fell 41 1 5 or 12 75 per share this made active efforts streamline operations reorganize both domestic overseas allow management focus resources into core areas looking ahead we have a number promising pharmaceutical compounds undergoing clinical trials in us europe including kw 6002 treatment parkinson disease which expect drive growth future said toshiaki mizutani manager investor relations department 3 an extraordinary loss 21 incurred from restructuring led
